[ad_1]
ANN ARBOR, Mich., May 29, 2019 / PRNewswire / – BlueWillow Biologics® today announced the issuance of US Patent Number 10,138,279 covering an intranasal NanoVax® anthrax vaccine. The patent, issued University of Michigan under exclusive license from BlueWillow, is based on research conducted by the University demonstrating the ability of the vaccine to induce long-term protection against the deadly anthrax virus in animals.
Lists from the National Institute of Allergic and Infectious Diseases (NIAID) Bacillus anthracis (anthrax) as a Clbad A pathogen, indicating that the biological agent poses the greatest possible risk to national security and public health. Exposure to anthrax can cause serious illness and death when spores enter the body through inhalation, indigestion or skin breaks. The disease is a huge threat in situations such as bioterrorism.
BlueWillow's intranasal NanoVax platform uses a new oil-in-water emulsion adjuvant that elicits systemic and mucosal immunity, thus uniquely protecting difficult respiratory infections. The advanced development of a NanoVax anthrax intranasal vaccine is underway as part of BlueWillow's partnership with Porton Biopharma Limited (PBL) of the United Kingdom. Phase 1 clinical trials are expected to begin in the second half of 2019.
PBL holds a contract (N ° HHSN272201600045C) from NIAID for the development of a new generation NanoVax anthrax vaccine, which could be worth up to $ 24 million over a period of eight years, if all options are exercised. The vaccine combines the new intranasal adjuvant from BlueWillow with the recombinant protective antigen of the PBL (rPA) anthrax. To date, the NanoVax anthrax vaccine has demonstrated safety, immunogenicity, and protection in many animal studies. In contrast, animals exposed to anthrax without first receiving NanoVax vaccine have not survived.
About BlueWillow
BlueWillow Organic Products® is a private biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on the development and commercialization of vaccines using its patented drug NanoVax® technological platform. The technology uses a novel nanoemulsion oil-in-water adjuvant that is effective when administered by intranasal or intramuscular vaccination and can induce both mucosal and systemic immunity during intranasal application.
BlueWillow is currently developing intranasal vaccines for several respiratory and badually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 infections, and chlamydia. Visit BlueWillow.com for more details on the company's vaccine pipeline and the studies completed to date.
SOURCE BlueWillow Organic Products
Related Links
http://BlueWillow.com
Source link
